The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended ...
The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
But a challenge to an Orange Book patent, should a brand-name manufacturer decide to fight in court, also delays a generic’s approval for 30 months. The FTC says that drugmakers needlessly list ...
The FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, GlaxoSmithKline and ...
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different ...
The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma and ...
The FTC argues those patents for altogether 20 brand-name products are “junk” listings that could be used by pharma companies to stymie competition and inflate drug prices. AstraZeneca ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the agency said inhibits the generic drug market.
disputing the accuracy of some 300 patent listings in the Food and Drug Administration’s so-called “Orange Book.” The crackdown, which comes six months after FTC challenged 10 pharma majors in a ...